Merck v Pharmascience, 2021 FC 1456 (Sitagliptin*)
Justice Furlanetto - 2021-12-21
Read full decision. Automatically generated summary:
This is a motion for reply evidence relating to an action under section 6(1) of the PMNOC Regulations. The sole patent that remains at issue is the 400 Patent, which is listed on the Patent Register in association with JANUVIA® (sitagliptin). The issues for trial include obviousness and insufficiency of disclosure. ... As set out further below, I find some of the opposed paragraphs to be appropriate reply while other paragraphs are not.
Decision relates to:
- T-419-20 - MERCK SHARP & DOHME CORP ET AL. v. PHARMASCIENCE INC.